Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK2 | P53671 | 1/20 | 0.51 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KIT | P10721 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12251021 | 0.93 | P2RY12 (0.49) | LIMK2P2RY12MAPK1ALDH1A1KIT | |
| SCHEMBL5573600 | 0.89 | TRPV1 (0.49) | LIMK2P2RY12PDGFRBFAAH | |
| SCHEMBL2423033 | 0.86 | KIT (0.48) | LIMK2P2RY12MAPK1ALDH1A1KIT | |
| SCHEMBL12251013 | 0.86 | PDGFRB (0.45) | P2RY12MAPK1MAPTPDGFRB | |
| SCHEMBL2385195 | 0.85 | PDGFRB (0.44) | P2RY12MAPK1KITMAPTPDGFRB | |
| SCHEMBL2401520 | 0.85 | MEN1 (0.50) | P2RY12MAPK1MAPTPDGFRB | |
| SCHEMBL12251020 | 0.85 | TRPV1 (0.48) | LIMK2KITPDGFRB | |
| SCHEMBL2384052 | 0.81 | LIMK2 (0.54) | LIMK2P2RY12MAPK1ALDH1A1KIT | |
| SCHEMBL2383727 | 0.80 | DRD2 (0.51) | P2RY12MAPK1ALDH1A1MAPTRAB9A | |
| SCHEMBL2384354 | 0.79 | RAB9A (0.47) | LIMK2P2RY12ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | claimed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | LIMK2 328/4885P2RY12 1298/4885MAPK1 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.